GFAP concentration in CSF is not an outstanding biomarker in patients with long‐standing SMA, but might support the hypothesis that glial activation is involved in SMA pathology and may be modulated by nusinersen treatment. The gene discussed is GFAP; the disease is proximal spinal muscular atrophy.